Abstract
Introduction: The recent approval of Spinraza (nusinersen), an antisense oligonucleotide, by U.S. Food and Drug Administration to treat patients with spinal muscular atrophy, has reignited interests of researchers in designing and testing new gene therapy approaches to treat neurological disorders, in particular, to curb neurodegenerative diseases of the central nervous system which represent an ever-increasing public health burden to today's society.
Conclusion: This review highlights several key factors to be taken into consideration to design successful preclinical and clinical gene therapy experiments with respect to the vehicle of delivery and the route of administration to CNS-specific targets, with an additional focus on antisense oligonucleotide therapy and recent clinical trial developments.
Keywords: Gene therapy, Neurodegenerative disorder, Antisense oligonucleotide, Clinical trial, Viral vectors, Central nervous system.
Current Gene Therapy
Title:Challenges and Advances in Gene Therapy Approaches for Neurodegenerative Disorders
Volume: 17 Issue: 3
Author(s): Aneesh Donde, Philip C. Wong and Liam L. Chen*
Affiliation:
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205,United States
Keywords: Gene therapy, Neurodegenerative disorder, Antisense oligonucleotide, Clinical trial, Viral vectors, Central nervous system.
Abstract: Introduction: The recent approval of Spinraza (nusinersen), an antisense oligonucleotide, by U.S. Food and Drug Administration to treat patients with spinal muscular atrophy, has reignited interests of researchers in designing and testing new gene therapy approaches to treat neurological disorders, in particular, to curb neurodegenerative diseases of the central nervous system which represent an ever-increasing public health burden to today's society.
Conclusion: This review highlights several key factors to be taken into consideration to design successful preclinical and clinical gene therapy experiments with respect to the vehicle of delivery and the route of administration to CNS-specific targets, with an additional focus on antisense oligonucleotide therapy and recent clinical trial developments.
Export Options
About this article
Cite this article as:
Donde Aneesh , Wong C. Philip and Chen L. Liam *, Challenges and Advances in Gene Therapy Approaches for Neurodegenerative Disorders, Current Gene Therapy 2017; 17 (3) . https://dx.doi.org/10.2174/1566523217666171013124150
DOI https://dx.doi.org/10.2174/1566523217666171013124150 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3
CNS & Neurological Disorders - Drug Targets Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Neural Stem Cell Transplantation and CNS Diseases
CNS & Neurological Disorders - Drug Targets Current Therapy and Computational Drug Designing Approaches for Neurodegenerative Diseases -with Focus on Alzheimer’s and Parkinson’s.
Current Signal Transduction Therapy Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy Epigenetic Mechanisms in Alzheimer's Disease
Current Medicinal Chemistry Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science Targeting PPARalpha in Alzheimer's Disease
Current Alzheimer Research Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Integrated Analysis of Transcriptomic and Proteomic Data
Current Genomics Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Editorial (Thematic Selection: Critical Analyses of Mechanism-Based Therapies Against Parkinson’s Disease: Concepts and Perspectives)
Current Neuropharmacology Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer’s disease
Current Pharmaceutical Design Protein Glycation: An Old Villain is Shedding Secrets
Combinatorial Chemistry & High Throughput Screening Non-Selective Cation Channel Blockers: Potential Use in Nervous System Basic Research and Therapeutics
Mini-Reviews in Medicinal Chemistry Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism